ASC2ESCALATE: A US, Phase II Open-Label, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Second-Line (2L) and First-Line (1L) Treatment of Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）
Key words
asciminib,chronic myeloid leukemia,CML,phase II,second line,first line,dose escalation
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined